PHARMALEX
PHARMALEX, a leading global provider of regulatory affairs, quality assurance, and compliance services, is headquartered in Great Britain. Founded in 1998, the company has established a strong presence across Europe, North America, and Asia, catering to the pharmaceutical, biotechnology, and medical device industries. With a focus on delivering tailored solutions, PHARMALEX offers a comprehensive range of services, including clinical trial management, market access strategies, and post-market surveillance. Their commitment to quality and regulatory excellence has positioned them as a trusted partner for clients navigating complex compliance landscapes. Recognised for their innovative approach and industry expertise, PHARMALEX continues to achieve significant milestones, solidifying their reputation as a key player in the life sciences sector.
DitchCarbon Score
How does PHARMALEX's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PHARMALEX's score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
PHARMALEX's reported carbon emissions
In 2021, PharmaLex, headquartered in Great Britain, reported total carbon emissions of approximately 1,487,150 kg CO2e. This figure includes Scope 1 emissions of about 27,080 kg CO2e, Scope 2 emissions of around 97,560 kg CO2e, and significant Scope 3 emissions totalling approximately 1,414,510 kg CO2e. The Scope 3 emissions breakdown reveals key contributors: business travel (62,000 kg CO2e), employee commute (333,000 kg CO2e), and purchased goods and services (1,007,000 kg CO2e). PharmaLex's emissions data is cascaded from its parent company, PharmaLex GmbH, indicating a corporate family relationship. However, the company has not set specific reduction targets or climate pledges as part of its sustainability initiatives. Overall, PharmaLex's commitment to addressing carbon emissions reflects the broader industry context, where companies are increasingly focusing on sustainability and climate action, despite the absence of formal reduction targets at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 27,080 |
| Scope 2 | 97,560 |
| Scope 3 | 1,416,510 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PHARMALEX is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
